

10/759,345

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

10/759,345

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:10:28 ON 01 AUG 2005

10/759,345

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADO
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items

10/759,345

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:54:20 ON 01 AUG 2005

=> e cidofovir/cn

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

The EXPAND command is used to look at the index in a file which has an index. This file does not have an index.

=> file reg

FIE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> e cidofovir/cn

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

The EXPAND command is used to look at the index in a file which has an index. This file does not have an index.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.42	0.42
------	------

FILE 'REGISTRY' ENTERED AT 12:55:10 ON 01 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2

DICTIONARY FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *

10/759,345

* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e cidofovir/cn

E1	1	CIDIROL/CN
E2	1	CIDOCETINE/CN
E3	1 -->	CIDOFOVIR/CN
E4	1	CIDOFOVIR DIPHOSPHATE/CN
E5	1	CIDOFOVIR HYDRATE/CN
E6	1	CIDOMYCIN/CN
E7	1	CIDOPHYLLINE/CN
E8	1	CIDOTEN/CN
E9	1	CIDOVIR/CN
E10	1	CIDOXEPIN/CN
E11	1	CIDOXEPIN HYDROCHLORIDE/CN
E12	1	CIDR/CN

=> s e3

L1 1 CIDOFOVIR/CN

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.03

5.45

FILE 'CAPLUS' ENTERED AT 12:55:31 ON 01 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Aug 2005 VOL 143 ISS 6

FILE LAST UPDATED: 31 Jul 2005 (20050731/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1

L2 563 L1

10/759,345

=> s 12 and alcohol
225925 ALCOHOL
155811 ALCOHOLS
353092 ALCOHOL
(ALCOHOL OR ALCOHOLS)
556434 ALC
184857 ALCS
650819 ALC
(ALC OR ALCS)
777558 ALCOHOL
(ALCOHOL OR ALC)
L3 35 L2 AND ALCOHOL

=> s 12 and (alkylglycerol or alkylpropanediol or alkylthioglycerol or
alkoxyalkanol or alkylethanediol)
193 ALKYLGLYCEROL
160 ALKYLGLYCEROLS
290 ALKYLGLYCEROL
(ALKYLGLYCEROL OR ALKYLGLYCEROLS)
21 ALKYLPROPANEDIOL
12 ALKYLPROPANEDIOLS
31 ALKYLPROPANEDIOL
(ALKYLPROPANEDIOL OR ALKYLPROPANEDIOLS)
2 ALKYLTHIOGLYCEROL
93 ALKOXYALKANOL
77 ALKOXYALKANOLS
139 ALKOXYALKANOL
(ALKOXYALKANOL OR ALKOXYALKANOLS)
3 ALKYLETHANEDIOL
3 ALKYLETHANEDIOLS
5 ALKYLETHANEDIOL
(ALKYLETHANEDIOL OR ALKYLETHANEDIOLS)
L4 6 L2 AND (ALKYLGLYCEROL OR ALKYLPROPANEDIOL OR ALKYLTHIOGLYCEROL
OR ALKOXYALKANOL OR ALKYLETHANEDIOL)

=> d 14 ibib hitstr abs 1-6


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:129464 CAPLUS
DOCUMENT NUMBER: 142:366750
TITLE: Comparison of the antiviral activities of alkoxyalkyl
and alkyl esters of cidofovir against human and murine
cytomegalovirus replication in vitro
AUTHOR(S): Wan, William B.; Beadle, James R.; Hartline, Carroll;
Kern, Earl R.; Ciesla, Stephanie L.; Valiaeva,
Nadejda; Hostetler, Karl Y.
CORPORATE SOURCE: Veterans Administration San Diego Healthcare System
and the Department of Medicine, University of
California, San Diego, La Jolla, CA, 92093-0676, USA
SOURCE: Antimicrobial Agents and Chemotherapy (2005), 49(2),
656-662
CODEN: AMACCQ; ISSN: 0066-4804
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 113852-37-2, Cidofovir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(comparison of antiviral activities of alkoxyalkyl and alkyl esters of

cidofovir against human and murine cytomegalovirus replication in vitro)

RN 113852-37-2 CAPLUS

CN Phosphonic acid, [[[1S]-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Alkoxyalkyl esters of cidofovir (CDV) have substantially greater antiviral activity and selectivity than unmodified CDV against herpesviruses and orthopoxviruses in vitro. Enhancement of antiviral activity was also noted when cyclic CDV was esterified with **alkoxyalkanols**. In vitro antiviral activity of the most active analogs against human cytomegalovirus (HCMV) and orthopoxviruses was increased relative to CDV up to 1000- or 200-fold, resp. Alkyl chain length and linker structure are important potential modifiers of antiviral activity and selectivity. In this study, the authors synthesized a series of alkoxyalkyl esters of CDV or cyclic CDV with alkyl chains from 8 to 24 atoms and having linker moieties of glycerol, propanediol, and ethanediol. The authors also synthesized alkyl esters of CDV which lack the linker to determine if the alkoxyalkyl linker moiety is required for activity. The new compds. were evaluated in vitro against HCMV and murine CMV (MCMV). CDV or cyclic CDV analogs both with and without linker moieties were highly active against HCMV and MCMV, and their activities were strongly dependent on chain length. The most active compds. had 20 atoms esterified to the phosphonate of CDV. Both alkoxypropyl and alkyl esters of CDV provided enhanced antiviral activities against CMV in vitro. Thus, the oxypropyl linker moiety is not required for enhanced activity. CDV analogs having alkyl ethers linked to glycerol or ethanediol linker groups also demonstrated increased activity against CMV.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:538061 CAPLUS

DOCUMENT NUMBER: 141:184637

TITLE: Antiviral prophylaxis of smallpox

AUTHOR(S): Bray, Mike; Roy, Chad J.

CORPORATE SOURCE: Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA

SOURCE: Journal of Antimicrobial Chemotherapy (2004), 54(1), 1-5

CODEN: JACHDX; ISSN: 0305-7453

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 113852-37-2, Cidofovir


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antiviral prophylaxis of smallpox)

RN 113852-37-2 CAPLUS

10/759,345

CN Phosphonic acid, [[[1S]-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A review. Proof-of-concept studies suggest that current defences against smallpox could be strengthened by supplementing vaccination with antiviral drug prophylaxis, based on aerosolized or orally available forms of the long-acting medication cidofovir. Delivery of aerosolized cidofovir to mice results in its prolonged retention in respiratory tissues and protection against lethal intranasal or aerosol poxviral challenge. Although cidofovir itself is not orally available, the addition of an **alkoxyalkanol** ether side-chain allows it to be absorbed from the gastrointestinal tract. This also markedly increases its antiviral activity and lengthens its intracellular half-life from roughly 3 to 8-10 days. Oral treatment also protected mice against lethal poxviral challenge. These results suggest that a single aerosol dose of cidofovir (or an **alkoxyalkanol**-ether derivative) could provide prolonged protection against initiation of smallpox infection, whereas oral treatment could prevent both initiation of infection and internal dissemination of virus. Both approaches may avoid the nephrotoxicity that occasionally results from i.v. cidofovir therapy.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:126286 CAPLUS

DOCUMENT NUMBER: 140:385553

TITLE: Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model

AUTHOR(S): Buller, R. Mark; Owens, Gelita; Schriewer, Jill; Melman, Lora; Beadle, James R.; Hostetler, Karl Y.

CORPORATE SOURCE: Department of Molecular Microbiology and Immunology, Saint Louis University Health Sciences Center, St. Louis, MO, 63104, USA

SOURCE: Virology (2004), 318(2), 474-481

CODEN: VIRLAX; ISSN: 0042-6822

PUBLISHER: Elsevier Science

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 113852-37-2, Cidofovir


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(efficacy of ether lipid analogs of cidofovir in lethal mousepox model)

RN 113852-37-2 CAPLUS

CN Phosphonic acid, [[[1S]-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Cidofovir (CDV) is a highly effective inhibitor of orthopoxvirus replication and may be used i.v. to treat smallpox or complications arising from the smallpox vaccine under an investigational new drug application (IND). However, CDV is absorbed poorly following oral administration and is inactive orally. To improve the bioavailability of CDV, others synthesized **alkoxyalkanols** esters of CDV and observed >100-fold more activity than unmodified CDV against cowpox, vaccinia, and variola virus (VARV) replication. These ether lipid analogs of CDV have high oral bioavailability in mice. In this study, we compared the oral activity of CDV with the hexadecyloxypropyl (HDP)-, octadecyloxyethyl-, oleyloxypropyl-, and oleyloxyethyl-esters of CDV in a lethal, aerosol ectromelia virus (ECTV) challenge model in A/NCR mice. Octadecyloxyethyl-CDV appeared to be the most potent CDV analog as a dose regimen of 5 mg/kg started 4 h following challenge completely blocked virus replication in spleen and liver, and protected 100% of A/NCR mice, although oral, unmodified CDV was inactive. These results suggest that this family of compds. deserves further evaluation as poxvirus.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:625949 CAPLUS

DOCUMENT NUMBER: 140:192122

TITLE: Esterification of cidofovir with **alkoxyalkanols** increases oral bioavailability and diminishes drug accumulation in kidney

AUTHOR(S): Ciesla, Stephanie L.; Trahan, Julissa; Wan, W. Brad; Beadle, James R.; Aldern, Kathy A.; Painter, George R.; Hostetler, Karl Y.

CORPORATE SOURCE: San Diego VA Healthcare System, Department of Medicine, University of California, La Jolla, CA, 92093-0676, USA

SOURCE: Antiviral Research (2003), 59(3), 163-171

CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 113852-37-2, Cidofovir


RL: PKT (Pharmacokinetics); BIOL (Biological study)

(esterification of cidofovir with **alkoxyalkanols** increases oral bioavailability and diminishes drug accumulation in kidney)

RN 113852-37-2 CAPLUS

CN Phosphonic acid; [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Smallpox was eradicated by vaccination in the 1970s. However, concerns have arisen about the potential use of variola virus as a biol. weapon. Most of the world's population has little residual immunity because systematic vaccination against smallpox ceased in the early 1970s. Vaccination of key elements of the population against smallpox is again being considered. However, there are now large nos. of persons who cannot be safely vaccinated with the current vaccine because of AIDS, immunosuppressive drugs, and certain common skin disorders. It would be useful to have a potent orally active drug as an alternative for these persons in case of an outbreak of smallpox. Alkoxyalkyl esters of cidofovir (CDV) have been shown to be highly active and selective against poxviruses in vitro with activities several logs greater than the activity of unmodified CDV. This is due in large part to increased cellular penetration and conversion to CDV-diphosphate, the active antiviral. In this paper, the oral pharmacokinetics of ¹⁴C-labeled hexadecyloxypropyl-cidofir (HDP-CDV), octadecyloxyethyl-cidofir (ODP-CDV), and oleyloxypropyl-cidofir (OLP-CDV) are examined and oral bioavailability and tissue distribution assessed and compared with parenteral CDV. The alkoxyalkyl CDVs are highly orally bioavailable and do not concentrate in kidney, the site of the dose-limiting toxicity of CDV. Plasma and tissue drug levels are many times greater than the in vitro EC₅₀s for variola, cowpox, and vaccinia viruses. Thus, the compds. are good candidates for further development for prevention and treatment of smallpox infection and the complications of vaccination.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:218837 CAPLUS

DOCUMENT NUMBER: 139:239732

TITLE: Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-¹⁴C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism

AUTHOR(S): Aldern, Kathy A.; Ciesla, Stephanie L.; Winegarden, Kristine L.; Hostetler, Karl Y.

CORPORATE SOURCE: Department of Medicine, San Diego VA Healthcare System and the University of California, La Jolla, CA, USA

SOURCE: Molecular Pharmacology (2003), 63(3), 678-681

CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 113852-37-2, Cidofovir


RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(increased antiviral activity of 1-O-hexadecyloxypropyl-[2-¹⁴C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism)

RN 113852-37-2 CAPLUS

CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB Recently, there has been renewed interest in finding orally active drugs against smallpox. Cidofovir (CDV) given by parenteral injection has been shown to protect against lethal poxvirus infection. We have been interested in the synthesis and evaluation of orally active derivs. of CDV. Previous studies showed that the CDV and cyclic cidofovir (cCDV) analogs 1-O-hexa-decyloxypropyl-CDV (HDP-CDV) and 1-O-hexadecyloxypropyl-cCDV (HDP-cCDV), show >100-fold increases in antiviral activity vs. the unmodified nucleosides against cells infected with orthopoxviruses, cowpox, and vaccinia virus. In contrast to CDV, HDP-CDV is orally bioavailable and has been reported to be orally active in lethal cowpox virus infection in mice. To assess the metabolic basis for the increased antiviral activity of HDP-CDV in vitro, we studied the cellular uptake and anabolic metabolism of ^{14}C -labeled CDV, cCDV, and their **alkoxyalkanol** esters HDP-CDV and HDP-cCDV. HDP-CDV and HDP-cCDV were taken up rapidly by MRC-5 human lung fibroblasts in vitro, but uptake of CDV and cCDV was much slower. Anal. of cellular metabolites showed that levels of cidofovir diphosphate (CDV-DP), the active antiviral compound, were >100 times greater with HDP-CDV than levels observed with CDV. When cells were exposed to HDP-CDV, the intracellular half-life of CDV-DP was 10 days vs. 2.7 days reported when cells are exposed to CDV. HDP-CDV seems to circumvent poor cellular uptake by rapid association with cellular membrane phospholipids, whereas CDV uptake proceeds via the slow process of fluid endocytosis.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:240052 CAPLUS

DOCUMENT NUMBER: 137:134473

TITLE: Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

AUTHOR(S): Kern, Earl R.; Hartline, Carol; Harden, Emma; Keith, Kathy; Rodriguez, Natalie; Beadle, James R.; Hostetler, Karl Y.

CORPORATE SOURCE: University of Alabama School of Medicine, Birmingham, AL, USA

SOURCE: Antimicrobial Agents and Chemotherapy (2002), 46(4), 991-995

CODEN: AMACCQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:134473

IT 113852-37-2, Cidofovir

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)


(enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir)

10/759,345

RN 113852-37-2 CAPLUS

CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The nucleotide phosphonates cidofovir (CDV) and cyclic cidofovir (cCDV) are potent antiviral compds. when administered parenterally but are not well absorbed orally. These compds. have been reported to have activity against orthopoxvirus replication in vitro and in animal models when administered parenterally or by aerosol. To obtain better oral activity, we synthesized a novel series of analogs of CDV and cCDV by esterification with two long-chain **alkoxyalkanols**, 3-hexadecyloxy-1-propanol (HDP-CDV; HDP-cCDV) or 3-octadecyloxy-1-ethanol (ODE-CDV; ODE-cCDV). Their activities were evaluated and compared with those of CDV and cCDV in human foreskin fibroblast (HFF) cells infected with vaccinia virus (VV) or cowpox virus (CV) using a plaque reduction assay. The 50% effective concns. (EC₅₀s) against VV in HFF cells for CDV and cCDV were 46.2 and 50.6 μ M compared with 0.84 and 3.8 μ M for HDP-CDV and HDP-cCDV, resp. The EC₅₀s for ODE-CDV and ODE-cCDV were 0.20 and 1.1 μ M, resp. The HDP analogs were 57- and 13-fold more active than the parent nucleotides, whereas the ODE analogs were 231- and 46-fold more active than the unmodified CDV and cCDV. Similar results were obtained using CV. Cytotoxicity studies indicated that although the analogs were more toxic than the parent nucleotides, the selective index was increased by 4- to 13-fold. These results indicate that the alkoxyalkyl esters of CDV and cCDV have enhanced activity in vitro and need to be evaluated for their oral absorption and efficacy in animal models.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

45.48	50.93
-------	-------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-4.38	-4.38
-------	-------

FILE 'REGISTRY' ENTERED AT 13:01:28 ON 01 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2

DICTIONARY FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e adefovir/cn

```
E1      1      ADEFLON A/CN
E2      1      ADEFLON D/CN
E3      1  --> ADEFOVIR/CN
E4      1      ADEFOVIR DIPHOSPHATE/CN
E5      1      ADEFOVIR DIPIVOXIL/CN
E6      1      ADEG/CN
E7      1      ADEHL/CN
E8      1      ADEK/CN
E9      1      ADEKA 1413/CN
E10     1      ADEKA 2014FG/CN
E11     1      ADEKA 25R1/CN
E12     1      ADEKA 25R2/CN
```

=> s e3

```
L5      1 ADEFOVIR/CN
```

=> e tenofovir/cn

```
E1      1      TENOBLOCK/CN
E2      1      TENOCYCLIDINE/CN
E3      1  --> TENOFOVIR/CN
E4      1      TENOFOVIR DF/CN
E5      1      TENOFOVIR DIPHOSPHATE/CN
E6      1      TENOFOVIR DISOPROXIL/CN
E7      1      TENOFOVIR DISOPROXIL FUMARATE/CN
E8      1      TENOFOVIR TRIPHOSPHATE/CN
E9      1      TENOLIN/CN
E10     1      TENOLOL/CN
E11     1      TENOMODULIN (HUMAN GENE TEM)/CN
E12     1      TENOMODULIN (HUMAN)/CN
```

=> s e3

```
L6      1 TENOFOVIR/CN
```

=> file caplus
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

10/759,345

FULL ESTIMATED COST	10.06	60.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.38

FILE 'CAPLUS' ENTERED AT 13:02:28 ON 01 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Aug 2005 VOL 143 ISS 6
FILE LAST UPDATED: 31 Jul 2005 (20050731/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5 or l6

493 L5

333 L6

L7 733 L5 OR L6

=> s l7 and (alkylglycerol or alkylpropanediol or alkylthioglycerol or alkoxyalkanol or alkylethanediol)

193 ALKYLGLYCEROL

160 ALKYLGLYCEROLS

290 ALKYLGLYCEROL

(ALKYLGLYCEROL OR ALKYLGLYCEROLS)

21 ALKYLPROPANEDIOL

12 ALKYLPROPANEDIOLS

31 ALKYLPROPANEDIOL

(ALKYLPROPANEDIOL OR ALKYLPROPANEDIOLS)

2 ALKYLTHIOGLYCEROL

93 ALKOXYALKANOL

77 ALKOXYALKANOLS

139 ALKOXYALKANOL

(ALKOXYALKANOL OR ALKOXYALKANOLS)

3 ALKYLETHANEDIOL

3 ALKYLETHANEDIOLS

5 ALKYLETHANEDIOL

(ALKYLETHANEDIOL OR ALKYLETHANEDIOLS)

L8 1 L7 AND (ALKYLGLYCEROL OR ALKYLPROPANEDIOL OR ALKYLTHIOGLYCEROL OR ALKOXYALKANOL OR ALKYLETHANEDIOL)

=> d l8 ibib hitstr abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

10/759,345

ACCESSION NUMBER: 2001:489223 CAPLUS
DOCUMENT NUMBER: 135:71256
TITLE: Phosphonoformate lipid analogs for the treatment of
drug-resistant human immunodeficiency virus infection
INVENTOR(S): Hostetler, Karl Y.; Mellors, John W.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047511	A2	20010705	WO 2000-US35137	20001222
WO 2001047511	A3	20011220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395430	AA	20010705	CA 2000-2395430	20001222
BR 2000016844	A	20020910	BR 2000-16844	20001222
EP 1244459	A2	20021002	EP 2000-988322	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518495	T2	20030610	JP 2001-548106	20001222
ZA 2002005020	A	20030626	ZA 2002-5020	20020621
US 2003207843	A1	20031106	US 2002-169432	20021030
PRIORITY APPLN. INFO.:			US 1999-173610P	P 19991229
			US 2000-174425P	P 20000104
			WO 2000-US35137	W 20001222


OTHER SOURCE(S): MARPAT 135:71256

IT 106941-25-7, Adefovir 147127-20-6, Tenofovir
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(resistance to; phosphonoformate lipid analogs for treatment of drug-resistant HIV infection)

RN 106941-25-7 CAPLUS

CN Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 147127-20-6 CAPLUS

CN Phosphonic acid, [[[1R]-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl]-

10/759,345

(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB Methods are provided for treating HIV infection in a subject in need thereof which use lipid analogs of phosphonoformate-containing pharmaceutically active compds. Lipid analogs contemplated for use comprise phosphonoformates covalently linked (directly or indirectly through a linker mol.) to a substituted or unsubstituted **alkylglycerol, alkylpropanediol, alkylethanol**, or related moiety. In particular, the invention provides methods for treating viral infections caused by viruses which have developed resistance to currently available antiviral agents, as well as methods comprising the use of invention compds. in combination with azidodeoxythymidine to minimize the selection of drug-resistant HIV variants during therapy.

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
16.64	77.63

FULL ESTIMATED COST


DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.73	-5.11

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:05:16 ON 01 AUG 2005

10/759,345



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

563 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
563 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e adefovir/cn

E1	1	ADEFLON A/CN
E2	1	ADEFLON D/CN
E3	1 -->	ADEFOVIR/CN
E4	1	ADEFOVIR DIPHOSPHATE/CN
E5	1	ADEFOVIR DIPIVOXIL/CN
E6	1	ADEG/CN
E7	1	ADEHL/CN
E8	1	ADEK/CN
E9	1	ADEKA 1413/CN
E10	1	ADEKA 2014FG/CN
E11	1	ADEKA 25R1/CN
E12	1	ADEKA 25R2/CN

=> s e3

L2 1 ADEFOVIR/CN

=> d l2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 106941-25-7 REGISTRY
ED Entered STN: 07 Mar 1987
CN Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 9-(2-Phosphonylmethoxyethyl)adenine
CN 9-[2-(Phosphonomethoxy)ethyl]adenine
CN **Adefovir**
CN GS 0393
CN PMEA
FS 3D CONCORD
MF C8 H12 N5 O4 P
CI COM
SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

10/759,345



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

493 REFERENCES IN FILE CA (1907 TO DATE)
24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
493 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e cyclic cidofovir/cn

E1	1	CYCLIC CARBOXYETHYL-AICAR-3',5'-MP/CN
E2	1	CYCLIC CHLOROETHYLENE CARBONATE/CN
E3	0 -->	CYCLIC CIDOFOVIR/CN
E4	1	CYCLIC CMP/CN
E5	1	CYCLIC CMP PHOSPHODIESTERASE/CN
E6	1	CYCLIC CYTIDINE 2',3'-PHOSPHATE AMMONIUM SALT/CN
E7	1	CYCLIC CYTIDINE MONOPHOSPHATE/CN
E8	1	CYCLIC D-TRYPTOPHANYL-L-TRYPTOPHAN/CN
E9	1	CYCLIC DAMP/CN
E10	1	CYCLIC DEOXYADENOSINE 3',5'-MONOPHOSPHATE/CN
E11	1	CYCLIC DI-GMP BINDING PROTEIN (BURKHOLDERIA PSEUDOMALLEI STR AIN K96243 GENE BCSB)/CN
E12	1	CYCLIC DI-GMP BINDING PROTEIN PRECURSOR (ESCHERICHIA COLI ST RAIN CFT073 GENE YHJN)/CN

=> e tenofovir/cn

E1	1	TENOBLOCK/CN
E2	1	TENOCYCLIDINE/CN
E3	1 -->	TENOFOVIR/CN
E4	1	TENOFOVIR DF/CN
E5	1	TENOFOVIR DIPHOSPHATE/CN
E6	1	TENOFOVIR DISOPROXIL/CN
E7	1	TENOFOVIR DISOPROXIL FUMARATE/CN
E8	1	TENOFOVIR TRIPHOSPHATE/CN
E9	1	TENOLIN/CN
E10	1	TENOLOL/CN
E11	1	TENOMODULIN (HUMAN GENE TEM)/CN
E12	1	TENOMODULIN (HUMAN)/CN

=> s e3

L3 1 TENOFOVIR/CN

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 147127-20-6 REGISTRY

ED Entered STN: 22 Apr 1993

CN Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, (R)-

OTHER NAMES:

CN (R)-9-(2-Phosphonomethoxypropyl)adenine


CN GS 1275

10/759,345

CN GS 1278
CN PMPA
CN **Tenofovir**
FS STEREOSEARCH
MF C9 H14 N5 O4 P
CI COM
SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, DIOGENES, EMBASE,
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PHAR, PROMT, PROUSDDR,
PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

327 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
333 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

23.19

23.67

STN INTERNATIONAL LOGOFF AT 12:46:09 ON 01 AUG 2005

10/759,345

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/Caplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/Caplus
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS	26	JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

10/759,345

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:40:19 ON 01 AUG 2005

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'STNGUIDE' ENTERED AT 12:40:33 ON 01 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 29, 2005 (20050729/UP).

=> FIL HOME

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

0.27

FILE 'HOME' ENTERED AT 12:40:38 ON 01 AUG 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.48

FILE 'REGISTRY' ENTERED AT 12:40:44 ON 01 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2

DICTIONARY FILE UPDATES: 29 JUL 2005 HIGHEST RN 857722-60-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

10/759,345

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> e cidofovir/cn

E1	1	CIDIROL/CN
E2	1	CIDOCETINE/CN
E3	1 -->	CIDOFOVIR/CN
E4	1	CIDOFOVIR DIPHOSPHATE/CN
E5	1	CIDOFOVIR HYDRATE/CN
E6	1	CIDOMYCIN/CN
E7	1	CIDOPHYLLINE/CN
E8	1	CIDOTEN/CN
E9	1	CIDOVIR/CN
E10	1	CIDOXEPIN/CN
E11	1	CIDOXEPIN HYDROCHLORIDE/CN
E12	1	CIDR/CN

=> s e3

L1 1 CIDOFOVIR/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 113852-37-2 REGISTRY

ED Entered STN: 16 Apr 1988

CN Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl]-, (S)-

OTHER NAMES:

CN (S)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine

CN (S)-HPMPC

CN 1-(S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine

CN 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine

CN Cidofovir

CN Cidovir

CN GS 0504

CN HPMPC

CN Vistide

FS STEREOSEARCH

MF C8 H14 N3 O6 P

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMINFORMRX, CHEMLIST, CIN, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)

Absolute stereochemistry.